Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design

被引：41

作者：

Jones, Spencer B. ^{[1
]}

Pfeifer, Lance A. ^{[1
]}

Bleisch, Thomas J. ^{[1
]}

Beauchamp, Thomas J. ^{[1
]}

Durbin, Jim D. ^{[1
]}

Klimkowski, V. Joseph ^{[1
]}

Hughes, Norman E. ^{[1
]}

Rito, Christopher J. ^{[1
]}

Dao, Yen ^{[1
]}

Gruber, Joseph M. ^{[1
,2
]}

Bui, Hai ^{[1
]}

Chambers, Mark G. ^{[1
]}

Chandrasekhar, Srinivasan ^{[1
]}

Lin, Chaohua ^{[1
]}

McCann, Denis J. ^{[1
]}

Mudra, Daniel R. ^{[1
]}

Oskins, Jennifer L. ^{[1
]}

Swearingen, Craig A. ^{[1
]}

Thirunavukkarasu, Kannan ^{[1
]}

Norman, Bryan H. ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

[2] Dow AgroSci, Zionsville, IN 46268 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 09期

关键词：

Autotaxin; tool molecule; osteoarthritis; LPA; LYSOPHOSPHATIDIC ACID PRODUCTION; ARTHRITIS; MOTILITY; SITE; LPA;

D O I：

10.1021/acsmedchemlett.6b00207

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In an effort to develop a novel therapeutic agent aimed at addressing the unmet need of patients with osteoarthritis pain, we set out to develop an inhibitor for autotaxin with excellent potency and physical properties to allow for the clinical investigation of autotaxin-induced nociceptive and neuropathic pain. An initial hit identification campaign led to an aminopyrimidine series with an autotaxin IC50 of 500 nM. X-ray crystallography enabled the optimization to a lead compound that demonstrated favorable potency (IC50 = 2 nM), PK properties, and a robust PK/PD relationship.

引用

页码：857 / 861

页数：5

共 50 条

[1] Identification of novel autotaxin inhibitors: Lead optimization through structure based drug design
Jones, Spencer
Pfeifer, Lance
Norman, Bryan
Hughes, Norman
Bleisch, Thomas
Beauchamp, Thomas
Rito, Christopher
Dao, Yen
Klimkowski, Valentine
Gruber, Joseph
Chambers, Mark
Swearingen, Craig
McCann, Denis
Mudra, Daniel
Durbin, Jim
Bui, Hai
Lin, Chaohua
Oskins, Jennifer
Chandrasekhar, Srinivasan
Thirunavukkarasu, Kannan
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[2] Structure-Based Design of Novel Boronic Acid-Based Inhibitors of Autotaxin
Abers, Harald M. H. G.
Hendrickx, Loes J. D.
van Tol, Rob J. P.
Hausmann, Jens
Perrakis, Anastassis
Ovaa, Huib
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (13) : 4619 - 4626
[3] Nonpeptide inhibitors of cathepsin G: Optimization of a novel β-ketophosphonic acid lead by structure-based drug design
Greco, Michael N.
Hawkins, Michael J.
Powell, Eugene T.
Almond, Jr., Harold R.
Corcoran, Thomas W.
De, Garavilla, Lawrence
Kauffman, Jack A.
Recacha, Rosario
Chattopadhyay, Debashish
Andrade-Gordon, Patricia
Maryanoff, Bruce E.
Journal of the American Chemical Society, 2002, 124 (15): : 3810 - 3811
[4] Nonpeptide inhibitors of cathepsin G:: Optimization of a novel β-ketophosphonic acid lead by structure-based drug design
Greco, MN
Hawkins, MJ
Powell, ET
Almond, HR
Corcoran, TW
de Garavilla, L
Kauffman, JA
Recacha, R
Chattopadhyay, D
Andrade-Gordon, P
Maryanoff, BE
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (15) : 3810 - 3811
[5] Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy
Gibson, Tony S.
Johnson, Benjamin
Fanjul, Andrea
Halkowycz, Petro
Dougan, Douglas R.
Cole, Derek
Swann, Steven
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (08) : 1709 - 1713
[6] Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy
Gibson, Tony
Johnson, Benjamin
Fanjul, Andrea
Halkowycz, Petro
Dougan, Douglas
Cole, Derek
Swann, Steve
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[7] Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors
Magkrioti, Christiana
Kaffe, Eleanna
Stylianaki, Elli-Anna
Sidahmet, Camelia
Melagraki, Georgia
Afantitis, Antreas
Matralis, Alexios N.
Aidinis, Vassilis
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) : 1 - 18
[8] Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors
Jessop, Theodore C.
Tarver, James E.
Carlsen, Marianne
Xu, Amy
Healy, Jason P.
Heim-Riether, Alexander
Fu, Qinghong
Taylor, Jerry A.
Augeri, David J.
Shen, Min
Stouch, Terry R.
Swanson, Ronald V.
Tari, Leslie W.
Hunter, Michael
Hoffman, Isaac
Keyes, Philip E.
Yu, Xuan-Chuan
Miranda, Maricar
Liu, Qingyun
Swaffield, Jonathan C.
Kimball, S. David
Nouraldeen, Amr
Wilson, Alan G. E.
Foushee, Ann Marie DiGeorge
Jhaver, Kanchan
Finch, Rick
Anderson, Steve
Oravecz, Tamas
Carson, Kenneth G.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (23) : 6784 - 6787
[9] Structure-based lead optimization of novel bacterial type II topoisomerase inhibitors
Pearson, Neil D.
Yang, Zheng
Bax, Benjamin D.
Gwynn, Michael N.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
[10] Discovery of novel α-amylase inhibitors using structure-based drug design
Jamil Al-Asri
Gerhard Wolber
Journal of Cheminformatics, 6 (Suppl 1)

← 1 2 3 4 5 →